Acalabrutinib
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Central Nervous System Lymphoma
Conditions
Central Nervous System Lymphoma
Trial Timeline
Oct 15, 2020 → Mar 14, 2030
NCT ID
NCT04548648About Acalabrutinib
Acalabrutinib is a phase 2 stage product being developed by AstraZeneca for Central Nervous System Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT04548648. Target conditions include Central Nervous System Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06757647 | Phase 2 | Recruiting |
| NCT06651970 | Approved | Recruiting |
| NCT06205498 | Pre-clinical | Active |
| NCT05256641 | Phase 1/2 | Recruiting |
| NCT05557695 | Pre-clinical | Recruiting |
| NCT04660045 | Phase 2 | Withdrawn |
| NCT05038904 | Phase 2 | Completed |
| NCT04198922 | Phase 2 | Active |
| NCT04548648 | Phase 2 | Active |
| NCT04497948 | Phase 1 | Terminated |
| NCT04380688 | Phase 2 | Completed |
| NCT04346199 | Phase 2 | Completed |
| NCT03932331 | Phase 1/2 | Active |
| NCT04008706 | Phase 3 | Completed |
| NCT03968848 | Phase 1 | Completed |
Competing Products
20 competing products in Central Nervous System Lymphoma